STATegics’ product pipeline is focused on allosteric small molecule modulators of clinically and commercially relevant cytokine receptors.   STATegics’ small molecules, Allomimetics, offer unique competitive advantages when compared to recombinant proteins or antibodies particularly when bioavailability in tissues or the central nervous system (CNS) is required.  STATegics’ lead programs target cytokine receptors that play fundamentally important roles in cell differentiation, organ protection or neuronal function. 

STATegics has discovered erythropoietin (EPO) Allomimetics with cytoprotective effects in cells expressing the tissue-protective EPO receptor.  Preclinical studies performed by STATegics and its collaborators have indicated beneficial effects of the lead compounds in several models of CNS diseases and organ protection in vitro and in vivo.  The program has been partially funded by grants from the Department of Defense, Friedreich's Ataxia Research Alliance (FARA), National Institute of Neurological Disorders and Stroke (NINDS), and The Michael J. Fox Foundation for Parkinson’s Research. 
STATegics is also advancing a 2nd generation thrombopoietin (TPO) mimetic in preclinical studies with the potential to address significant needs in the treatment of patients with low platelet counts.  The lead compound also demonstrates anti-proliferative effects in leukemia cells suggesting potential in the treatment of bone marrow malignancies.  STATegics' lead
TPO Allomimetics are covered by US patents No. 7,786,159 and No. 8,143,287. 

STATegics’ strategy is to advance its proprietary compounds through preclinical stages and early clinical development independently, while seeking to work in partnership with other biotechnology and pharmaceutical companies toward later stage development and commercialization. Revlogosmaller

 STATegics, Inc., all rights reserved.
  Site Map